For years, cancer patients using ivermectin were told the same thing by their oncologists: “There is no human clinical data. Come back when there is.”
That excuse is running out of time.
Ivermectin clinical trials in cancer are now underway at major US institutions — including the National Cancer Institute itself. And what happens over the next 12 to 24 months could change the entire conversation.
The Story So Far
The mechanistic case for ivermectin in cancer has been built for over a decade:
- Over 50 preclinical studies — peer-reviewed and published — documenting multi-target anti-cancer activity
- Confirmed inhibition of Wnt/β-catenin, YAP/Hippo, PAK1, mTOR, and mitochondrial function
- Documented effects on cancer stem cells, apoptosis, angiogenesis, immune modulation, and drug resistance reversal
- Decades of safety data from billions of doses used worldwide as an antiparasitic drug
But no human cancer trials. That gap has been the single biggest obstacle preventing oncologists from taking ivermectin seriously — even when the biology screamed for it.
That gap is now closing.
What Is Happening Right Now
1. The NCI Is Now Studying Ivermectin
In February 2026, the National Cancer Institute publicly confirmed that it is studying ivermectin’s ability to kill cancer cells.
NCI Director Dr. Anthony Letai stated:
“There are enough reports of it, enough interest in it, that we actually did engage in a better preclinical study of its properties and its ability to kill cancer cells.”
This is significant. The NCI is not known for chasing fringe compounds. When it publicly confirms it is running preclinical validation on an off-patent, cheap drug, it is because the signal in the literature has become impossible to ignore.
2. Cedars-Sinai — Phase I/II Trial
The first serious human trial is already generating data.
Cedars-Sinai Medical Center is running a Phase I/II trial of oral ivermectin combined with immune checkpoint inhibitors in metastatic triple-negative breast cancer — one of the most aggressive and treatment-resistant cancers.
Early data presented at ASCO 2025 showed:
- Safe and well tolerated, even in combination with immunotherapy
- 37.5% clinical benefit rate in heavily pretreated patients — patients who had already failed multiple prior lines of treatment
For metastatic triple-negative breast cancer, that number is remarkable. This is a cancer where standard second- and third-line therapies often produce single-digit response rates.
3. ICONIC Trial — University of Florida
The ICONIC trial at the University of Florida is evaluating ivermectin combined with immune checkpoint inhibitors in advanced solid tumors.
Phase 1 is focused on:
- Safety — establishing tolerable dosing when combined with immunotherapy
- Immune modulation — measuring how ivermectin changes the tumor immune environment
- Dose response — identifying the therapeutic sweet spot
Estimated completion: late 2027.
Between Cedars-Sinai and Florida, we are looking at two major US academic institutions running real clinical trials on ivermectin in cancer — with immune checkpoint inhibitors, in advanced disease, in patients who have already exhausted conventional options.
Why This Matters — And Why It Doesn’t
Let me be direct.
For me personally, I do not need a clinical trial to prove ivermectin is effective against cancer. The preclinical mechanisms are clear. The pathways it targets are well documented. And I have seen the results in practice for years.
But these trials matter — not for people who already understand the mechanistic case — but for the millions of cancer patients whose oncologists will not consider ivermectin without Phase 3 data. It matters for the medical students who are being taught to laugh at anyone bringing up repurposed drugs. It matters for the insurance system that refuses to acknowledge anything without institutional validation.
Institutional validation is not the same as biological truth. But it is what moves a drug from “fringe” to “standard of care.”
That is what these trials will do. They will move the ivermectin conversation from social media into the exam room. From YouTube into the hospital pharmacy. From dismissal into discussion.
What This Means for You
If you are already using ivermectin as part of a comprehensive cancer protocol — this is validation. The data is starting to catch up with what you already knew.
If you are considering ivermectin — the mechanistic case has always been strong. The safety profile has always been excellent. What is changing now is that you will increasingly be able to have an honest conversation about it with an oncologist, instead of a fight.
If your oncologist has been dismissive — the ground is shifting under them. The compound they refused to discuss last year is now being tested at the NCI. Bring these trials to the next appointment. Ask them to look at the ASCO 2025 data.
The Bottom Line
The preclinical data on ivermectin in cancer was always strong. What was missing was institutional validation. That is now arriving.
- NCI is running preclinical validation studies — as of February 2026
- Cedars-Sinai Phase I/II data — 37.5% clinical benefit rate in metastatic TNBC
- ICONIC trial at University of Florida — ongoing through 2027
The next 12 to 24 months could change the entire landscape of how ivermectin is discussed in oncology.
But even with these trials underway, one thing has not changed: ivermectin is not a stand-alone solution. It is one component of a comprehensive Targeted Metabolic Therapy protocol — combined with dietary strategies, fasting, other repurposed drugs, nutraceuticals, vitamins, minerals, adjunct therapies, and lifestyle changes.
The patients who benefit the most from ivermectin are not the ones taking it alone. They are the ones using it inside a real protocol — with the terrain prepared, the drug interactions understood, the liver supported, and the biology monitored.
That is what the data will eventually confirm. And that is what serious cancer treatment already looks like today.